Recent Updates
Recently added Catalysts

Metastatic Urothelial Cancer: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$214Muniverse median $1.20B
Allocated capital$54M$214M competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank285/299crowding rank 285

Metastatic Urothelial Cancer is uncontested. Bicycle Therapeutics (BCYC) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Zelenectide pevedotin in phase 2.

There is no public comparable to price it against. BCYC spreads its $214M market cap across 4 indications, so $54M of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$54M of allocated capital sits in Metastatic Urothelial Cancer, ranking it 285th of 299 indications by the money committed to it.

Companies developing drugs for Metastatic Urothelial Cancer 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
BCYCBicycle TherapeuticsZelenectide pevedotinPhase 21$214MNo4 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Metastatic Urothelial Cancer counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Metastatic Urothelial Cancer has one competitor and a median of $214M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Metastatic Pancreatic Adenocarcinoma1 company · $53M · median $371MUncontestedNewly Diagnosed Glioblastoma1 company · $53M · median $371MUncontestedMetastatic Anal Cancer1 company · $51M · median $102MUncontestedAdenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma1 company · $64M · median $129MUncontestedPediatric Brain Tumor1 company · $41M · median $124MUncontestedAggressive B-Cell Non-Hodgkin's Lymphoma1 company · $34M · median $168MUncontestedFollicular Lymphoma1 company · $34M · median $168MUncontestedLow-Grade Serous Ovarian Carcinoma1 company · $90M · median $723MUncontested

Metastatic Urothelial Cancer pipeline questions

Which biotech companies are developing drugs for Metastatic Urothelial Cancer?

Bicycle Therapeutics (BCYC, Zelenectide pevedotin, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Metastatic Urothelial Cancer.

How advanced is the Metastatic Urothelial Cancer pipeline?

Of the 1 clinical-stage programme in Metastatic Urothelial Cancer, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Metastatic Urothelial Cancer?

No. BCYC is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Metastatic Urothelial Cancer, which is why the indication is classified as uncontested.

When is the next Metastatic Urothelial Cancer catalyst?

The next dated catalyst in Metastatic Urothelial Cancer is BCYC on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map